RENEW OR SUBSCRIBE TO PPM
Subscription is FREE for qualified healthcare professionals in the US.

Ubrogepant Shows Positive Results for Acute Treatment of Migraines

Phase 3 subjects achieved pain relief after two hours when compared to a placebo

In the Pipeline - A PPM Brief 
 

Migraine headaches are an extraordinarily common neurological disease, affecting 39 million people in the United States alone.1 More than four million migraine sufferers have chronic daily migraines, or at least 15 migraines per month.1 Yet, the disease is often under-diagnosed, leaving migraine sufferers without effective relief from the pain and related symptoms.

An oral CGRP receptor antagonist in Phase 3 testing by Allergan (Dublin) may soon offer a new treatment option for acute migraine pain. ACHIEVE I, the first of two Phase 3 clinical trials evaluating the efficacy, safety, and tolerability of ubrogepant, included 1,327 adult participants. Subjects either received 50 mg or 100 mg of ubrogepant or placebo to treat a single migraine attack of moderate or severe intensity.2

“There remains a need for new treatments with improved benefit-risk profiles,” said lead investigator Richard B. Lipton, MD, vice chair of neurology and director of the Montefiore Headache Center in a company release. “Results from this ubrogepant phase 3 trial are important in progressing the research and developing therapies to help migraine patients.”

Both the 50 mg and 100 mg doses had a statistically significant greater percentage of pain relief at two hours after the initial dose compared to placebo (50 mg vs placebo, P = 0.0023, 100 mg vs placebo, P = 0.0003). Both doses also demonstrated a statistically significant greater percentage in absence of the most bothersome migraine-associated symptom at two hours after the initial dose compared to placebo (50 mg vs placebo, P = 0.0023, 100 mg vs placebo, P = 0.0023).2

Adverse events of ubrogepant were comparable to placebo, with the most common being nausea, somnolence, and dry mouth, none of which were reported with a frequency of greater than 5%.2 Liver issues were minimal, with instances of high aminotransferase levels in participants being accompanied by alternative explanations, such as illness or medication, none of which were noted by the liver safety adjudication board as having a probable relationship to ubrogepant.2

“We are confident that ubrogepant will be an option for the treatment of migraines in adults,” said Allergan’s Chief Research & Development Office David Nicholson in a company release.

Additional results from the study, including the second Phase 3 trial (ACHIEVE II), are forthcoming.2

Last updated on: February 9, 2018
Continue Reading:
Skin Patch Resolves Migraine Pain More Quickly with Fewer Side Effects
SHOW MAIN MENU
SHOW SUB MENU